

July 29, 2024

Q1FY25 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Cui	rent	Prev	ious
	FY25E	FY26E	FY25E	FY26E
Rating	RED	DUCE	REI	DUCE
Target Price	2,	743	2,	414
Sales (Rs. m)	62,962	68,146	61,826	66,671
% Chng.	1.8	2.2		
EBITDA (Rs. m) 21,329	22,962	20,441	22,285
% Chng.	4.3	3.0		
EPS (Rs.)	56.1	60.0	53.2	57.7
% Chng.	5.5	4.0		

Key Financials - Standalone

Y/e Mar	FY23	FY24	FY25E	FY26E
Sales (Rs. m)	52,262	56,805	62,962	68,146
EBITDA (Rs. m)	15,470	18,985	21,329	22,962
Margin (%)	29.6	33.4	33.9	33.7
PAT (Rs. m)	10,584	13,410	15,272	16,318
EPS (Rs.)	38.9	49.3	56.1	60.0
Gr. (%)	(1.9)	26.7	13.9	6.8
DPS (Rs.)	39.0	58.0	50.0	51.0
Yield (%)	1.2	1.8	1.6	1.6
RoE (%)	61.3	74.7	82.5	83.5
RoCE (%)	79.5	96.2	105.4	107.8
EV/Sales (x)	16.5	15.1	13.6	12.6
EV/EBITDA (x)	55.8	45.3	40.3	37.3
PE (x)	82.5	65.1	57.2	53.5
P/BV (x)	50.9	46.6	47.7	42.0

Key Data	COLG.BO CLGT IN
52-W High / Low	Rs.3,272 / Rs.1,902
Sensex / Nifty	81,356 / 24,836
Market Cap	Rs.873bn/\$ 10,426m
Shares Outstanding	272m
3M Avg. Daily Value	Rs.1227.66m

Shareholding Pattern (%)

Promoter's	51.00
Foreign	24.44
Domestic Institution	6.01
Public & Others	18.55
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	12.9	27.5	57.2
Relative	9.7	12.8	27.9

Amnish Aggarwal

amnishaggarwal@plindia.com | 91-22-66322233

Hasti Sav la

hastisavla@plindia.com |

Vishwa Solanki

vishwasolanki@plindia.com | 91-22-66322244

Colgate Palmolive (CLGT IN)

Rating: REDUCE | CMP: Rs3,210 | TP: Rs2,743

Volumes complement margin expansion

Quick Pointers:

- 8% toothpaste volume growth aided by strong rural demand in core portfolio
- Double digit sales growth in Toothpaste, toothbrush & personal care

CLGT delivered yet another strong quarter with pick up in volumes resulting in ~8% toothpaste volume growth and double-digit sales growth across all segments. 220bps expansion in Gross margins and 40bps decline in Ad spends resulted in 240bps expansion in EBIDTA margins to 34%. Core portfolio led by Colgate strong teeth, Active salt and total reported strong growth supplemented by double-digit sales growth in toothbrush after several quarters. Incremental pricing actions remained limited in view of benign pricing which helped improve consumer value.

We increase our FY25/26/27 estimates by 5.5%/4%/4.6% on pick up in volumes led by rural demand revival, low volume base and benefit of benign raw materials. CLGT continues to focus on 1) driving toothpaste category penetration and twice a day usage in urban India 2) science-based innovations with Total and Colgate strong teeth 3) build personal care portfolio in body/hand/face wash and 4) increasing usage of toothbrush by reducing the replacement cycle. We expect margin expansion to slow down in coming quarters given base of 32.8, 33.6 and 35.7 in 2Q/3Q/4Q versus 31.6% in 1Q25. We estimate 10.2% EPS CAGR over FY24-26. We value CLGT at 45x FY26 EPS (42x earlier) and assign a target of Rs2743 (Rs2414 earlier). CLGT trades at 52.7x Jun-26 EPS. Retain Reduce

Sales grew 13.1%, EBITDA Margins expand by 237bps YoY: Revenues grew by 13.1% YoY to Rs15bn (PLe: Rs14.5bn) Gross margins expanded by 222bps YoY to 70.6% (Ple: 69.5%) EBITDA grew by 21.6% YoY to Rs5.1bn (PLe:Rs4.6bn); Margins expanded by 238bps YoY to 34% (PLe:32.1%) A&P spends contracted by 40bps YoY to 13.3% Adj. PAT grew by 24.1% YoY to Rs3.6bn (PLe:Rs3.2bn)

Key Highlights

- We estimate ~8% volume growth for 1Q with balance growth led by pricing & premiumisation, pricing growth has peaked out.
- Both Toothpaste and Toothbrush reported double-digit revenue growth. Core portfolio led by Colgate Strong teeth drove growth in toothpaste segment.
- Rural recovery continues with demand in rural markets outpacing urban markets for the second consecutive quarter.
- CLGT launched Whitening booster gel as a one of a kind product in its Whitening segment.
- CLGT continues its focus on category growth through "Brush at Night" campaign & sustained investment on superior communication which is responsible for its strong growth trajectory leading to its highest historic levels.




Exhibit 1: 1QFY25: Net sales up 13.1%, EBITDA margins expand by 237bps YoY to 34%

Particulars	1Q FY25	1Q FY24	Yo Y gr. (%)	4Q FY24	FY24	FY23	Yo Y gr. (%)
Net Sales	14,967	13,237	13.1	14,900	56,804	52,262	8.7
Gross Profit	10,574	9,058	16.7	10,327	39,574	34,320	15.3
Margin %	70.6	68.4	2.2	69.3	69.7	65.7	4.0
Other Exp	5490	4877	12.6	5005	20566	18850	9.1
% of Net sales	36.7	36.8	(0.4)	33.6	36.2	36.1	0.1
EBITDA	5,083	4,181	21.6	5,322	19,008	15,470	22.9
Margin %	34.0	31.6	2.4	35.7	33.5	29.6	3.9
Depreciation	415	438	(5.1)	421	1715	1748	(1.9)
Interest	10	11	(8.4)	14	50	49	1.8
PBT from operations	4659	3733	24.8	4887	17243	13673	26.1
Other Income	234	150	56.3	227	765	536	42.8
PBT	4,893	3,883	26.0	5,114	18,008	14,209	26.7
Tax	1253	951	31.8	1315	4577	3625	26.2
Tax rate %	25.6	24.5	4.6	25.7	25.4	25.5	(0.1)
Adj. PAT	3,640	2,932	24.1	3,798	13,432	10,584	26.9

Source: Company, PL

Exhibit 2: Toothpaste volumes grow ~8% in 1Q25



Source: Company, PL



Financials

lnoome	Statement	/Dc ml
HICOILLE	: Statement	IRS III I

Income Statement (Rs m)				
Y/e Mar	FY23	FY24	FY25E	FY26E
Net Revenues	52,262	56,805	62,962	68,146
YoY gr. (%)	2.5	8.7	10.8	8.2
Cost of Goods Sold	17,942	17,230	18,574	20,209
Gross Profit	34,320	39,575	44,388	47,937
Margin (%)	65.7	69.7	70.5	70.3
Employ ee Cost	3,770	4,117	4,506	4,878
Other Expenses	4,096	3,869	4,937	5,344
EBITDA	15,470	18,985	21,329	22,962
YoY gr. (%)	(1.2)	22.7	12.3	7.7
Margin (%)	29.6	33. <i>4</i>	33.9	33.7
Depreciation and Amortization	1,748	1,715	1,819	1,915
EBIT	13,722	17,270	19,510	21,048
Margin (%)	26.3	30.4	31.0	30.9
Net Interest	49	50	54	53
Other Income	536	767	960	820
Profit Before Tax	14,209	17,987	20,417	21,815
Margin (%)	27.2	31.7	32.4	32.0
Total Tax	3,625	4,577	5,145	5,497
Effective tax rate (%)	25.5	25.4	25.2	25.2
Profit after tax	10,584	13,410	15,272	16,318
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	10,584	13,410	15,272	16,318
YoY gr. (%)	(1.9)	26.7	13.9	6.8
Margin (%)	20.3	23.6	24.3	23.9
Extra Ord. Income / (Exp)	(112)	(195)	-	-
Reported PAT	10,471	13,215	15,272	16,318
YoY gr. (%)	(2.9)	26.2	15.6	6.8
Margin (%)	20.0	23.3	24.3	23.9
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	10,471	13,215	15,272	16,318
Equity Shares O/s (m)	272	272	272	272
EPS (Rs)	38.9	49.3	56.1	60.0

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Balance Sheet Abstract (Rs	m)			
Y/e Mar	FY23	FY24	FY25E	FY26E
Non-Current Assets				
Gross Block	18,885	19,748	20,557	21,582
Tangibles	18,885	19,748	20,557	21,582
Intangibles	-	=	-	-
Acc: Dep / Amortization	11,679	13,181	14,784	16,468
Tangibles	11,679	13,181	14,784	16,468
Intangibles	-	-	-	-
Net fixed assets	7,205	6,567	5,773	5,114
Tangibles	7,205	6,567	5,773	5,114
Intangibles	-	-	-	-
Capital Work In Progress	1,141	1,103	1,100	1,200
Goodwill	-	-	-	-
Non-Current Investments	195	178	187	196
Net Deferred tax assets	288	648	-	-
Other Non-Current Assets	4,522	4,432	4,491	4,516
Current Assets				
Investments	7,964	8,783	10,013	10,840
Inv entories	3,354	2,964	4,011	4,359
Trade receivables	1,574	1,674	2,058	2,227
Cash & Bank Balance	1,266	4,955	3,950	6,526
Other Current Assets	381	535	469	508
Total Assets	28,830	31,965	32,191	35,630
Equity				
Equity Share Capital	272	272	272	272
Other Equity	16,892	18,472	18,020	20,502
Total Networth	17,164	18,744	18,292	20,774
Non-Current Liabilities				
Long Term borrowings	-	-	-	-
Provisions	236	216	270	293
Other non current liabilities	571	599	376	312
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	7,611	8,819	9,430	10,208
Other current liabilities	3,235	3,574	3,809	4,030
Total Equity & Liabilities	28,830	31,965	32,191	35,630

Source: Company Data, PL Research



Cash Flow (Rs m)				
Y/e Mar	FY23	FY24	FY25E	FY26E
PBT	14,209	17,985	20,417	21,815
Add. Depreciation	1,748	1,715	1,819	1,915
Add. Interest	49	50	54	53
Less Financial Other Income	536	767	960	820
Add. Other	(112)	(195)	-	-
Op. profit before WC changes	15,894	19,555	22,289	23,783
Net Changes-WC	(106)	1,393	(1,377)	(495)
Direct tax	(3,625)	(4,577)	(5,190)	(5,546)
Net cash from Op. activities	12,163	16,372	15,723	17,742
Capital expenditures	(659)	(1,000)	(995)	(1,326)
Interest / Dividend Income	-	-	-	-
Others	-	-	-	-
Net Cash from Invt. activities	(659)	(1,000)	(995)	(1,326)
Issue of share cap. / premium	(47)	4,141	(2,079)	84
Debt changes	-	-	-	-
Div idend paid	(10,607)	(15,775)	(13,599)	(13,871)
Interest paid	(49)	(50)	(54)	(53)
Others	-	-	-	-
Net cash from Fin. activities	(10,704)	(11,684)	(15,732)	(13,840)
Net change in cash	801	3,688	(1,004)	2,575
Free Cash Flow	11,504	15,372	14,728	16,415

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q2FY24	Q3FY24	Q4FY24	Q1FY25
Net Revenue	14,711	13,957	14,900	14,967
YoY gr. (%)	6.0	8.1	10.3	13.1
Raw Material Expenses	4,594	3,883	4,573	4,393
Gross Profit	10,117	10,073	10,327	10,574
Margin (%)	68.8	72.2	69.3	70.6
EBITDA	4,821	4,684	5,322	5,083
YoY gr. (%)	18.2	29.6	17.8	21.6
Margin (%)	32.8	33.6	35.7	34.0
Depreciation / Depletion	443	414	421	415
EBIT	4,379	4,270	4,901	4,668
Margin (%)	29.8	30.6	32.9	31.2
Net Interest	11	15	14	10
Other Income	210	179	227	234
Profit before Tax	4,578	4,434	5,114	4,893
Margin (%)	31.1	31.8	34.3	32.7
Total Tax	1,178	1,133	1,315	1,253
Effective tax rate (%)	25.7	25.6	25.7	25.6
Profit after Tax	3,401	3,301	3,798	3,640
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	3,401	3,301	3,798	3,640
YoY gr. (%)	22.3	35.7	19.4	24.1
Margin (%)	23.1	23.7	25.5	24 .3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,401	3,301	3,798	3,640
YoY gr. (%)	22.3	35.7	20.1	33.0
Margin (%)	23.1	23.7	25.5	24 .3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,401	3,301	3,798	3,640
Av g. Shares O/s (m)	272	272	-	272
EPS (Rs)	12.5	12.1	-	13.4

Source: Company Data, PL Research

Y/e Mar	FY23	FY24	FY25E	FY26E
Per Share(Rs)				
EPS	38.9	49.3	56.1	60.0
CEPS	45.3	55.6	62.8	67.0
BVPS	63.1	68.9	67.3	76.4
FCF	42.3	56.5	54.1	60.4
DPS	39.0	58.0	50.0	51.0
Return Ratio(%)				
RoCE	79.5	96.2	105.4	107.8
ROIC	127.4	305.4	320.4	726.4
RoE	61.3	74.7	82.5	83.5
Balance Sheet				
Net Debt : Equity (x)	(0.5)	(0.7)	(0.8)	(0.8)
Net Working Capital (Days)	(19)	(27)	(19)	(19)
Valuation(x)				
PER	82.5	65.1	57.2	53.5
P/B	50.9	46.6	47.7	42.0
P/CEPS	70.8	57.7	51.1	47.9
EV/EBITDA	55.8	45.3	40.3	37.3
EV/Sales	16.5	15.1	13.6	12.6
Dividend Yield (%)	1.2	1.8	1.6	1.6

Source: Company Data, PL Research





Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Asian Paints	Reduce	2,605	2,974
2	Avenue Supermarts	Accumulate	5,104	4,944
3	Britannia Industries	Hold	5,315	5,547
4	Colgate Palmolive	Reduce	2,414	2,910
5	Dabur India	UR	-	606
6	Emami	UR	-	725
7	Hindustan Unilever	Hold	2,698	2,766
8	ПС	Accumulate	491	434
9	Jubilant FoodWorks	UR	-	570
10	Kansai Nerolac Paints	Reduce	266	267
11	Marico	Accumulate	621	615
12	Metro Brands	Hold	1,190	1,218
13	Mold-tek Packaging	Accumulate	843	796
14	Nestle India	Accumulate	2,746	2,481
15	Pidilite Industries	Accumulate	3,141	3,100
16	Restaurant Brands Asia	Accumulate	134	114
17	Titan Company	Accumulate	3,545	3,269
18	Westlife Foodw orld	Hold	791	833

PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Amnish Aggarwal- MBA, CFA, Ms. Hasti Savla- CA, Mr. Vishwa Solanki- PGDM - Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that. All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (marginfunding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Amnish Aggarwal-MBA, CFA, Ms. Hasti Savla-CA, Mr. Vishwa Solanki-PGDM - Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Poloor another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com